Results for tag: "Cannabis Capsule"

The Cannabis Capsule market operates as a subset of the broader analgesic (pain relief) industry, focusing on products derived from Cannabis sativa plants. These capsules are designed to deliver cannabinoids, primarily cannabidiol (CBD), and sometimes tetrahydrocannabinol (THC), in precise doses. They offer an alternative to traditional pain management solutions, appearing attractive to patients seeking the purported anti-inflammatory, neuroprotective, and analgesic effects of cannabinoids without inhalation. Additionally, these capsules often appeal to those desiring discretion and convenience, as they lack the odor and ritual associated with smoking or vaporizing cannabis. Cannabis capsules are subject to varying legal and regulatory frameworks that differ by region, which shapes market dynamics and accessibility. These products are commonly found in regions with legalized medicinal or adult-use cannabis. Manufacturers emphasize the consistency, quality control, and standardized dosing of these products to distinguish them from less regulated cannabis-based preparations. In the market of cannabis-infused capsules for pain management, several companies play notable roles. Among these are Tilray, which offers a range of medical cannabis products, including capsules; Canopy Growth Corporation, known for its extensive portfolio of cannabis brands and products; Aurora Cannabis, which produces a variety of medicinal cannabis products; and GW Pharmaceuticals, well-known for its research-driven approach and pharmaceutical-grade cannabis-derived products. Each of these companies contributes to the diversity and availability of capsules within the field of analgesics. Show Less Read more